Loading stock data…
Beta Bionics, Inc. (BBNX)
$19.33-0.09 (-0.46%)
Market ClosedLast close Sep 8
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Beta Bionics, Inc. in the Healthcare sector is trading at $19.33 with a market capitalization of $804M. Wall Street consensus targets $20.31 (11 analysts), implying a +5.1% move over the next 12 months. The stock is currently 41% below its 52-week high of $32.71, remaining 15.7% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +5.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $32.01M↑ | $27.63M↓ | $32.12M↑ | $27.25M↑ | $23.24M |
| Gross Profit | $18.90M↑ | $16.44M↓ | $18.94M↑ | $15.12M↑ | $12.50M |
| Operating Income | -$25.58M↓ | -$24.27M↓ | -$16.12M↑ | -$17.04M↑ | -$19.87M |
| Net Income | -$23.40M↓ | -$21.89M↓ | -$13.47M↑ | -$14.21M↑ | -$16.87M |
Peer Comparison
JNJUNHPFE
Fundamentals
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$803.97M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-28.46%
Volume
Today's trading volume
900,487
Recent News
Beta Bionics (BBNX) Q2 2026 Earnings Call Transcript
Pharmacy channel sales surged 153% as new patient starts accelerated.
Beta Bionics, Inc. Q2 2026 Earnings Call Summary
Moby summary of Beta Bionics, Inc.'s Q2 2026 earnings call
Beta Bionics Q2 Earnings Call Highlights
Beta Bionics (NASDAQ:BBNX) reported second-quarter 2026 net sales of $32 million, up approximately 38% from a year earlier, as new patient starts and recurring pharmacy-channel supply revenue supported growth for its iLet insulin-delivery system. Chief Executive Officer Sean Saint said the company’
Beta Bionics, Inc. (BBNX) Reports Q2 Loss, Tops Revenue Estimates
Beta Bionics, Inc. (BBNX) delivered earnings and revenue surprises of +14.52% and +2.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Beta Bionics (BBNX) Stock Fair Value Falls As Medtech Reset Tempers iLet And Mint Optimism
The fair value estimate for Beta Bionics has moved from US$31.30 to US$19.80 per share, which places it closer to the current cluster of analyst price targets between US$13 and US$22. Recent commentary links this reset to a balance between optimism around iLet and the planned Mint launch, and caution related to medtech valuation resets and sector headwinds. As you read on, you will see how this shifting narrative and new assumptions might shape how you track Beta Bionics from here. Analyst...